AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01823770 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo patchs
Description: Subject randomized on the placebo group will be treated with placebo patchs, following the same modalities and study periods that the rotigotine arm
Study NCT02133742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Axitinib at starting dose of 5 mg and 3 mg BID.
Study NCT02133742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475
Description: MK-3475 with two dose levels: 2 mg/kg every three weeks to find the maximum tolerated dose and continue treatment in a dose expansion phase.
Study NCT02148211 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Initial and follow-up data was collected using questionnaires.
Study NCT04261049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide Extended-Release Injectable Suspension
Description: A single ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) intra-articular knee injection.
Study NCT00860418 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pediatric Asthma Alert (PAAL)
Description: Asthma nurse conducts 2 home visits and accompanies the child to primary care provider visit after ED visits
Study NCT00860418 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard asthma education
Description: Standard asthma education during 2 home visits.
Study NCT02027415 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beet juice
Description: 2 cups of beet juice will be given before the car ride
Study NCT00987714 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Protocolized care
Description: Organ Procurement Coordinators will utilize a hemodynamic monitor and algorithm for donor management of cardiac index, pulse pressure variation and mean arterial pressure.
Study NCT04218812 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: No electrical source imaging (ESI)
Description: For all patients: MRI, semiology, visual interpretation of EEG, and in selected cases, PET, SPECT
Study NCT04218812 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: No electrical source imaging (ESI)
Description: For all patients: MRI, semiology, visual interpretation of EEG, and in selected cases, PET, SPECT
Study NCT04218812 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Automated electrical source imaging (ESI)
Description: The automated source imaging consists of 2 phases~1. Automated detection of EDs~2. Source imaging of each spike cluster and seizure onset epoch.
Study NCT04218812 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Automated electrical source imaging (ESI)
Description: The automated source imaging consists of 2 phases~1. Automated detection of EDs~2. Source imaging of each spike cluster and seizure onset epoch.
Study NCT01312519 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OnControl Bone Marrow Biopsy and Aspiration System
Description: Battery powered device used for insertion of a single lumen catheter into the intraosseous space of the adult iliac crest for the purpose of aspiration and core biopsy collection.
Study NCT01312519 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual bone marrow sampling device
Description: Hollow needle with a t-shaped handle that is pushed into the bone for the purpose of collecting bone marrow aspiration and core biopsy samples.
Study NCT01261364 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GeneSightRx
Description: Multi-genetic pharmacogenomic panel
Study NCT01261364 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual
Study NCT04414540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Extended Release Oral Tablet
Description: Metformin ER starting dose 1000mg daily Metformin ER escalation dose 2000mg daily
Study NCT04414540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab q 3 weeks
Study NCT03950258 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endovascular embolization
Description: Transarterial embolization is done for patients with arteriovenous shunts as via transfemoral access using flow-guided microcatheter and an embolic agent is injected.
Study NCT04265339 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smoking cessation
Description: Participants are required to quit smoking
Study NCT01867944 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perineal Self-Acupressure
Description: The core of the technique is to have subjects repeatedly press on and massage their perineum before defecation to fragment and soften the stool before it passes the lower rectum and anus.
Study NCT01867944 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Control
Description: Education on conventional treatment options for chronic constipation.
Study NCT02288390 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oral care in mechanically ventilated patients
Description: Oral care comparing Chlorhexidine and toothbrush versus Miswak ( the twig of Arak, Salvadora perscia, tree)
Study NCT03174951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVIg
Description: Patients will take 400mg/kg IVIg at the time of positive pregnancy,Following the first administration, IVIG well given every 4 weeks through 32 weeks of gestation.
Study NCT01284296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine digital block
Description: One dose of lidocaine 2% injected locally into one finger (2 mls total)
Study NCT01284296 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Masimo SpHb continuous hemoglobin monitor
Description: Masimo SpHb continuous hemoglobin monitor
Study NCT00446836 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel polyglumex (Xyotax)
Description: biologically enhanced chemotherapeutic
Study NCT00418821 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Laronidase
Description: dose of 0.58mg/kg body weight intravenously (IV) every week
Study NCT00968292 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental prosthetics foot (K3 Promoter)
Description: The tests will be unblinded randomized studies of the subject's current prosthetic foot and the K3 Promoter on traumatic/congenital amputees and dysvascular/diabetic amputees. Assessments will be made after a 30-day accommodation period with each foot prosthesis. In order to randomize the treatment and factor out habituation to the testing site and the protocol, two cohorts will be used. Half of the volunteers will be randomly assigned to be fitted with the K3 Promoter by their regular prosthetist or will continue wearing their current foot prothesis. Both cohorts will have a 30-day accommodation period. Subjects in either cohort will then visit the CGMA to be tested. Volunteers will then use the other prosthesis for 30 days. After that second 30-day period, height and weight will again be recorded, and the tests will be repeated. Because of anticipated difficulty with scheduling, volunteers will be given a +3 day grace period on the 30 day-accommodation time.
Study NCT04213976 — intervention group
Intervention type: PROCEDURE
Intervention: Ileostomy
Description: Use of an ileostomy to decompress the proximal bowel, perfored either as a conventional loop ileostomy or as described by Santulli et al. or by Bishop and Koop.
Study NCT03785392 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group 1 In-plane
Description: Group 1: Study will involve total of 15 patients with the procedure done in-plane. Before the block placement and after the block placement lung function will be measured.~FEV1 (forced expiratory volume in 1 second ) and FVC ( forced vital Capacity ) values will be recorded. Block will be performed in plane and postprocedure lung function test will be repeated. New values of FEV1 and FVC will be obtained after the placement of the nerve block.
Study NCT03785392 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group 2 out of plane
Description: Group 2 study will adopt the out of plane technique and will involve a total of 15 patients in this group. We will do the procedure out of plane and will have lung function FEV1 and FVC measured bedside.FEV1 and FVC values will be recorded. Block will be performed out of plane and postprocedure lung function test will be measured. New values of FEV1 and FVC will be obtained
Study NCT03346486 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control diet
Description: Regular diet
Study NCT03346486 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intervention diet
Description: Brainfood dietary regime planned to be optimal for metabolism and cognitive function; having focus on regular meal frequency (breakfast, lunch and afternoon snack) and well-balanced light lunch at work according to the so-called plate model and optimized recipes- will be provided.
Study NCT01985334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrronium
Description: Glycopyrronium 50 µg capsule for inhalation via SDDPI once per day
Study NCT01495325 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Forearm Vascular Study
Description: Forearm venous occlusion plethysmography to measure forearm blood flow during intra-arterial infusion of the vasodilators Verapamil (10-100 µg/min), bradykinin (100-1000 pmol/min), sodium nitroprusside (2-8 µg/min) and Acetylcholine (5-20 µg/min).
Study NCT02027415 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Orange juice
Description: 2 cups of orange juice will be given before the car ride
Study NCT04014270 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self-modulated functional electrical stimulation (SM-FES)
Description: The patient actively self-administers the electrical stimulation on the impaired limb by controlling the electrical stimulation device with the non-impaired hand. A device called the Intento PRO will be used to deliver the experimental treatment.~Duration: 90 min per day, 5 days per week, for 2 weeks.
Study NCT04014270 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: The patient performs intensive, goal-oriented, repetitive functional exercises.~Duration: 90 min per day, 5 days per week, for 2 weeks.
Study NCT04097015 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alpha-Stim M
Description: Alpha-Stim M with and Ocular Interface and a Spinal Interface
Study NCT03226561 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phaco / Panoptix
Description: Phacoemulsification with bilateral diffractive trifocal lens implantation
Study NCT03443609 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 68Ga-HBED-CC-PSMA PET / CT
Description: Patient will receive a specific PET / CT with PSMA
Study NCT03428451 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NaCl 3% HS
Description: Hypertonic saline 3% is a type of crystalloid solution with osmolarity higher than that of plasma.
Study NCT03428451 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NaCl 3% HS
Description: Hypertonic saline 3% is a type of crystalloid solutions with osmolarity higher than that of plasma.
Study NCT03428451 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NaCl 0.9% NS
Description: Normal saline 0.9% is a type of crystalloid solution with osmolarity similar to that of plasma.
Study NCT01042951 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ShanChol Cholera Vaccine
Description: 55 adults (18-45 year old) will be given 2 doses of the bivalent whole-cell cholera vaccine 55 Toddlers(2-5 years) will be given 2 doses of the bivalent whole-cell cholera vaccine 55 Younger children(12-23 months)will be given 2 doses of the bivalent whole-cell cholera vaccine
Study NCT01495325 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Forearm Vascular Study
Description: Forearm venous occlusion plethysmography to measure forearm blood flow during intra-arterial infusion of the vasodilators Verapamil (10-100 µg/min), bradykinin (100-1000 pmol/min), sodium nitroprusside (2-8 µg/min) and Acetylcholine (5-20 µg/min).
Study NCT01495325 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Badimon Chamber
Description: Ex-vivo assessment of thrombus formation using the Badimon Chamber
Study NCT01495325 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Badimon Chamber
Description: Ex-vivo assessment of thrombus formation using the Badimon Chamber
Study NCT01985334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SABA
Description: Short-acting β2-adrenergic agonist (SABA) as per approved by each country and as prescribed for each patient, used as background therapy
Study NCT01985334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LABA
Description: Long Acting Beta Agonist (LABA) as per approved by each country and as prescribed for each patient, used as background therapy
Study NCT01042951 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 55 adults (18-45 year old) will be given 2 doses placebo, 55 Toddlers(2-5 years) will be given 2 doses of placebo, and 55 Younger children(12-23 months)will be given 2 doses of placebo
Study NCT04354779 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: a specifically designed self-administered questionnaire
Description: The questionnaire consists of the following items: questions related to personal health, traveling activities, living situation, as well as inquiries of symptoms and comorbidities.
Study NCT00886418 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: muscle relaxant
Description: muscle relaxant administration throughout anesthesia
Study NCT00886418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: normal saline
Description: no muscle relaxant throughout anesthesia (normal saline infused as a placebo)
Study NCT02562183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: kallikrein
Description: Using kallikrein
Study NCT04496557 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PROCESS-INSTRUCTED SELF NEURO-MODULATION (PRISM)
Description: Neurofeedback sessions targeting down-regulation of deep limbic structures, specifically the amygdala, delievered via PRISM: a non-significant risk device (software) intended to be used in research studies testing the clinical efficacy of an innovative paradigm for EEG-based neurofeedback.~The study will include 12 EEG-NF sessions, administered twice per week for a duration of 6 active weeks in total. Twice weekly sessions will be held on non-consecutive days. Each session will last 30 minutes.~EFP-EEG-NF training: Each NF training session consists of 5 consecutive sequences of NF presentations. During a watch condition (60 seconds) participants are instructed to passively view the animation, and are told that that the scenario does not influence their brain activity. In the regulate phase (60 seconds) participants are instructed to lower the room's unrest level. A rest phase (15 seconds) follows each sequence, allowing participants to relax.
Study NCT05278286 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Crawling stimulation with the crawliskate
Description: Consists of 2 months of daily training. Infants benefit from a 5 minutes session everyday at home with a trained therapist. During each session the infant is prone wrapped on the crawliskate and has to produce flexion and extension movements with his four limbs in order to move forward with the assistance of the therapist.
Study NCT05278286 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tummy time without the crawliskate
Description: Consists of 2 months of daily training. Infants benefit from a 5-minutes session everyday at home with a trained therapist. During each session the infant is prone directly ona mattress and cannot benefit from any assistance from the therapist to move forward.
Study NCT01343017 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ventilatory pattern
Description: In group one, increased tidal volume with a adjusted apparatus dead space volume (IVT), In group two, normal tidal volume with a PEEP to 10 cmH2O applied(NVT). PETCO2 will be adjusted to maintain at 4.5 kPa, in both groups. When PETCO2 values were stable at 4.5 kPa, sevoflurane administration will be started with a vaporiser set to 3%. After 5 minutes the fresh gas flow will be adjusted to 1.0 L/min with an unchanged vaporiser setting throughout the anaesthesia period.
Study NCT02016469 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: co-transplantation of FMT and pectin
Description: 300ml Bacterial suspension (from 60g fresh stool )for fecal microbiota transplantation the first day and 20g pectin given continuously for total five days
Study NCT02016469 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: single fecal microbiota transplantation
Description: single fecal microbiota transplantation once the first day
Study NCT02016469 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: pure give pectin 20g/d for five days
Description: pure give pectin 20g/d for five days
Study NCT01779648 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DVT-3000
Study NCT01779648 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SCD Express
Study NCT06182540 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mango puree
Description: Mango puree 300g
Study NCT01867567 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: abdominal bandage
Study NCT01867567 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: abdominal bandage
Study NCT02861053 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: regular and moderate physical activity
Description: regular and moderate physical activity will be done 3 times per week more than usual
Study NCT02861053 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: regular and moderate physical activity
Description: regular and moderate physical activity will be done 3 times per week more than usual
Study NCT02861053 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No regular and moderate physical activity more than usual
Description: regular and moderate physical activity will be done as usual
Study NCT02861053 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No regular and moderate physical activity more than usual
Description: regular and moderate physical activity will be done as usual
Study NCT02800720 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation Awareness Training
Description: 8 Week Meditation Intervention
Study NCT02800720 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy for Groups
Description: 8 week intervention based on Cognitive Behavioral Theory
Study NCT03979846 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Receive usual care
Study NCT03979846 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer Application
Description: Use computer-based symptom reporting system
Study NCT03979846 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03979846 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04254432 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: remote ischemic conditioning
Description: RIC is a physical strategy performed by an electric auto-control device with cuffs placed on unilateral arms and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures are performed repeatedly for 5 times# two times per day. The duration of the treatment is 4 weeks.
Study NCT03594253 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regulation Focused Psychotherapy for Children
Description: RFP-C is a manualized, psychodynamic psychotherapy that last 10 weeks. Children meet individually with a therapist for play therapy (twice a week for 16 sessions) and parents meet with the therapist for four full sessions (without the child).
Study NCT02137837 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fulvestrant
Study NCT02137837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Study NCT02137837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Study NCT02137837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Study NCT02137837 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Anastrozole
Study NCT02137837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - Anastrozole
Study NCT02137837 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Everolimus